These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 7657286

  • 1. Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. GTIP Gruppo Triveneto per l'Ipertensione Portale.
    Merkel C, Gatta A, Donada C, Enzo E, Marin R, Amodio P, Torboli P, Angeli P, Cavallarin G, Sebastianelli G.
    Hepatology; 1995 Sep; 22(3):808-13. PubMed ID: 7657286
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis.
    Merkel C, Marin R, Sacerdoti D, Donada C, Cavallarin G, Torboli P, Amodio P, Sebastianelli G, Bolognesi M, Felder M, Mazzaro C, Gatta A.
    Hepatology; 2000 Feb; 31(2):324-9. PubMed ID: 10655253
    [Abstract] [Full Text] [Related]

  • 4. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone.
    Merkel C, Sacerdoti D, Bolognesi M, Enzo E, Marin R, Bombonato G, Angeli P, Gatta A.
    Hepatology; 1997 Jul; 26(1):34-9. PubMed ID: 9214449
    [Abstract] [Full Text] [Related]

  • 5. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding.
    Villanueva C, Balanzó J, Novella MT, Soriano G, Sáinz S, Torras X, Cussó X, Guarner C, Vilardell F.
    N Engl J Med; 1996 Jun 20; 334(25):1624-9. PubMed ID: 8628357
    [Abstract] [Full Text] [Related]

  • 6. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites.
    Borroni G, Salerno F, Cazzaniga M, Bissoli F, Lorenzano E, Maggi A, Visentin S, Panzeri A, de Franchis R.
    J Hepatol; 2002 Sep 20; 37(3):315-21. PubMed ID: 12175626
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of endoscopic variceal ligation and nadolol plus isosorbide-5-mononitrate in the prevention of first variceal bleeding in cirrhotic patients.
    Wang HM, Lo GH, Chen WC, Tsai WL, Chan HH, Cheng LC, Hsu PI, Lai KH.
    J Chin Med Assoc; 2006 Oct 20; 69(10):453-60. PubMed ID: 17098669
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding.
    Lo GH, Chen WC, Wang HM, Yu HC.
    J Gastroenterol Hepatol; 2012 Nov 20; 27(11):1681-7. PubMed ID: 22849337
    [Abstract] [Full Text] [Related]

  • 14. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding.
    Villanueva C, Miñana J, Ortiz J, Gallego A, Soriano G, Torras X, Sáinz S, Boadas J, Cussó X, Guarner C, Balanzó J.
    N Engl J Med; 2001 Aug 30; 345(9):647-55. PubMed ID: 11547718
    [Abstract] [Full Text] [Related]

  • 15. Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis.
    Merkel C, Sacerdoti D, Bolognesi M, Buonamico P, Sticca A, Amodio P, Angeli P, Micotti L, Gatta A.
    Eur J Gastroenterol Hepatol; 1999 Nov 30; 11(11):1221-5. PubMed ID: 10563530
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis.
    Villanueva C, López-Balaguer JM, Aracil C, Kolle L, González B, Miñana J, Soriano G, Guarner C, Balanzó J.
    J Hepatol; 2004 May 30; 40(5):757-65. PubMed ID: 15094222
    [Abstract] [Full Text] [Related]

  • 19. Long-term administration of isosorbide-5-mononitrate does not impair renal function in cirrhotic patients.
    Salerno F, Borroni G, Lorenzano E, Solenghi D, Cazzaniga M, Bissoli F, Ceriani R, deFranchis R.
    Hepatology; 1996 May 30; 23(5):1135-40. PubMed ID: 8621145
    [Abstract] [Full Text] [Related]

  • 20. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding.
    Lo GH, Chen WC, Chen MH, Hsu PI, Lin CK, Tsai WL, Lai KH.
    Gastroenterology; 2002 Sep 30; 123(3):728-34. PubMed ID: 12198699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.